Subject: Specialty Quantity Limit Rinvoq 3175-H P2023a
Policy:
I. PROGRAM DESCRIPTION
The standard limit is designed to allow a quantity sufficient for
the most common uses of the medication. If the member’s plan
allows a quantity limit exception review for the requested
medication, coverage of an additional quantity may be provided
up to the exception limit with prior authorization.
II. COVERED QUANTITIES
|
Medication
|
Standard Limit
|
Exception Limit*
|
FDA-recommended dosing
|
|
Rinvoq
(upadacitinib)
15 mg extended-
release tablet
|
30 tablets
per 30 days
|
N/A
|
RA, PsA, AS, nr-axSpA: 15 mg once daily
Atopic dermatitis
• Pediatric patients 12 years of age and
older weighing at least 40 kg and adults
less than 65 years of age:
º Initiate treatment with 15 mg once
daily. A dosage of 30 mg once daily
may be considered if an adequate
response is not achieved.
• Dose adjustments: Reduce to 15 mg
once daily for patients:
º 65 years of age and older
º With severe renal impairment (not
recommended for patients with end
stage renal disease)
º Receiving strong CYP3A4 inhibitors
Ulcerative colitis
• Induction dose of 45 mg once daily for
8 weeks
• Maintenance dose of 15 mg once daily.
A dosage of 30 mg once daily may be
considered for patients with refractory,
severe or extensive disease
• Dose adjustments: Induction dose of
30 mg once daily for 8 weeks and
maintenance dose of 15 mg once daily
for patients:
º With severe renal impairment
º With mild to moderate hepatic
impairment (Child-Pugh A or B)
º Receiving strong CYP3A4 inhibitors
Crohn’s disease
• Induction dose of 45 mg once daily for
12 weeks
• Maintenance dose of 15 mg once daily.
A dosage of 30 mg once daily may be
considered for patients with refractory,
severe or extensive disease
• Dose adjustments: Induction dose of
30 mg once daily for 12 weeks and
maintenance dose of 15 mg once daily
for patients:
º With severe renal impairment
º With mild to moderate hepatic
impairment (Child-Pugh A or B)
º Receiving strong CYP3A4 inhibitors
|
|
Rinvoq
(upadacitinib)
30 mg extended-
release tablet
|
30 tablets
per 30 days
|
N/A
|
|
Rinvoq (upadacitinib)
45 mg extended-
release tablet
|
No standard
limit - only used
for induction
dosing
|
84 tablets per 84 days
|
Abbreviations: RA = rheumatoid arthritis, PsA = psoriatic arthritis; AS = ankylosing spondylitis; nr-axSpA = non-radiographic axial spondyloarthritis
*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.
Place of Service:
Outpatient
The above policy is based on the following references:
- Rinvoq [package insert]. North Chicago, IL: AbbVie Inc.; May 2023.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
July 26, 2023
